Casdin Capital’s Keros Therapeutics KROS Stock Holding History

Casdin Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-65,000	Closed	-$3.12M	–	44
2022 Q4	$3.12M	Buy	+65,000	New	+$3.04M	0.24%	41

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Casdin Capital's KROS Position: Q1 2023 in Review

Casdin Capital sold out of Keros Therapeutics (KROS) in Q1 2023, closing a stake of 65,000 shares — an estimated $3.12M sold.

Casdin Capital first reported a position in KROS in Q4 2022 and held it in 1 quarter. The position peaked at $3.12M in Q4 2022. 129 funds tracked by Wall St. Rank hold KROS as of Q1 2023.

Casdin Capital reported no remaining Keros Therapeutics position as of Q1 2023 after selling out during the quarter.
Casdin Capital sold 65,000 Keros Therapeutics shares in Q1 2023, an estimated $3.12M.
Casdin Capital first reported a position in Keros Therapeutics in Q4 2022 and held it in 1 quarter.
Casdin Capital's Keros Therapeutics position peaked at $3.12M in Q4 2022.
129 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2023.

Based on Casdin Capital's 13F filing for Q1 2023, filed 15 May 2023.